Quality of Life and Adverse Effects in Epilepsy Patients (EPIKA)

Quality of Life and Adverse Effects in Epilepsy Patients According to Treatment Group (EPIKA)

Observational, multicentre, epidemiological study to determine the HRQOL of patients with epilepsy according to treatment sub-group and to validate the Spanish version of the Adverse Events Profile, produced by G. Baker et al. Three treatment groups will be examined: patients receiving only a new anti-epilepsy drug (AED), patients receiving a "classic" AED; patients receiving combination therapy.

Inclusion Criteria:

• Epileptic adult patients treated at a stable dose with one or more AEDs for ≥ 3 months

Exclusion Criteria:

• Symptomatic epilepsy due to malignant brain tumour or progressive brain disease.
• Confirmed diagnosis of a concomitant chronic disease